已传文件：photo/1769491065.png
Abstract:
Bone metastasis presents a core challenge characterized by the interdependence of immunosuppression, neuropathic pain, and bone resorption, which existing treatments struggle to comprehensively address. In this study, we developed a reactive oxygen species (ROS)-responsive liposomal nanoplatform to co-deliver a STING agonist and GSDMB plasmid, achieving dual neuro-immune modulation.After selective activation by the tumor at metastatic bone sites, this platform can induce STING-driven immune activation and GSDMB-mediated pyroptosis, while restoring VGCC expression as a prognostic biomarker, blocking calcium-dependent neural signals to disrupt tumor-neural interactions, thereby establishing a novel neuro-immune therapy platform and providing an effective solution for dismantling the metastatic niche.
Research Background
Bone metastasis is a major unsolved challenge in the field of oncology. Its key pathological features involve a complex network in which immunosuppression, neuropathic pain, and bone degradation mutually reinforce each other. Current treatment methods can only target individual pathological aspects and are unable to comprehensively regulate these interconnected pathophysiological pathways, highlighting an urgent need to develop innovative therapeutic strategies that can simultaneously address multiple issues.
Original Source:
Authors: Zhaowei Zhang, Pengfei Chen, Yufei Zheng, Mobai Li, Lan Zhao, Zezhou Fu, Yujie Zhou, Tingyu Zhang, Xuanrong Sun, Dingcheng Zhu, Youqing Shen, Shunwu Fan, Xin Liu, Jiajia Xiang
Pub Date: 2026-01-23
DOI: 10.1126/sciadv.ady1292
Journal: ACS Nano
